Please select the option that best describes you:

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?  

Should patients with moderate penetrance pathogenic variants be managed similar to BRCA patients and consider risk reducing contralateral mastectomy? 



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
https://www.redjournal.org/article/S0360-3016(21)0...
Medical Oncologist at Memorial Sloan Kettering Cancer Center
Thanks. These data are somewhat reassuring but imp...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more